GLP-1s were added to the Essential Medicines List for diabetes but not for obesity, despite WHOs obesity treatment guidelines, published in December 2025, recommending their use
It originated from Emispheres Eligen platform, and the IP ultimately ended up under Novo Nordisks umbrella
To qualify, patients must: Be 18 years or older, non-pregnant Have a Body Mass Index (BMI) of 30 kg/m, or Have a BMI of 25 kg/m with at least one obesity-related risk factor (e.g., hypertension, diabetes) While semaglutide is an effective weight management tool, it is not for everyone
According to NICE guidance (NG28), treatment intensification should be individualised based on HbA1c targets, hypoglycaemia risk, and patient preferences
Das macht sie vor allem fr empfindlichere Haut oder fr Personen interessant, die strkere Wirkstoffe nicht gut vertragen
Quva also highlighted BrightStream, an AI-enabled platform that aggregates and normalizes fragmented health-system data to support the drug-shortage management, inventory optimization, diversion reduction, and formulary decision-making